Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for
metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Clovis Oncology, Inc. National Cancer Institute (NCI)